Understanding the Relationship Between Amphetamines and Psychosis

Current Addiction Reports

Volumn 2, Issue 4, 2015, Pages 285-292

  Rognli, Eline Borger ^a,b,c   Bramness, Jørgen G ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c Sykehuset Innlandet Helseforetaket   (Norway)

Author keywords

Amphetamine; Methamphetamine; Psychosis; Schizophrenia; Stimulants; Substance induced

Indexed keywords

EID: 84971395447     PISSN: None     EISSN: 21962952     Source Type: Journal    
DOI: 10.1007/s40429-015-0077-4     Document Type: Review

References (88)

1. Edeleano L. Über einige Derivate der Phenylmethacrylsäure und der Phenylisobuttersäure., in Berichte der Deutschen chemischen Gesellschaft zu Berlin. 1887: Berlin. p. 616–22.
2. Suwaki H, Fukui S, Konuma K. Methamphetamine abuse in Japan: its 45 year history and the current situation. In: Klee H, editor. Amphetamine misuse: international perspectives on current trends. Amsterdam: Harwood Academic Publishers; 1997. p. 199–214.
3. Prinzmetal M, Bloomberg W. The use of benzedrine for the treatment of narcolepsy. JAMA. 1935;105(25):2051–4.
4. Young D, Scoville WB. Paranoid psychoses in narcolepsy and possible danger of benzedrine treatment. Med Clin N Am. 1938;22:637–45.
5. UNODC. World drug report 2011. Vienna: United Nations Office on Drugs and Crime; 2012.
6. Degenhardt L, Hall W. Extent of illicit drug use and dependence, and their contribution to the global burden of disease. Lancet. 2012;379(9810):55–70.
7. Marshall BD, Werb D. Health outcomes associated with methamphetamine use among young people: a systematic review. Addiction. 2010;105(6):991–1002.
8. Grant KM et al. Methamphetamine-associated psychosis. J Neuroimmune Pharmacol. 2012;7(1):113–39. The author provides a thorough review of the phenomenon methamphetamine-induced psychosis (MAP), with description of risk factors and symptoms. The article shows the equivocal boundaries of MAP and the complexity in determining whether the psychosis is secondary to substance use or a primary psychosis in substance-using individuals.
9. Angrist BM, Gershon S. The phenomenology of experimentally induced amphetamine psychosis—preliminary observations. Biol Psychiatry. 1970;2(2):95–107.
10. Bell DS. The experimental reproduction of amphetamine psychosis. Arch Gen Psychiatry. 1973;29(1):35–40.
11. Griffiths JD, Oates J, Cavanaugh J. Paranoid episodes induced by drug. JAMA. 1968;205:39.
12. McKetin R et al. The risk of psychotic symptoms associated with recreational methamphetamine use. Drug Alcohol Rev. 2010;29(4):358–63.
13. McKetin R et al. The prevalence of psychotic symptoms among methamphetamine users. Addiction. 2006;101(10):1473–8.
14. McKetin R et al. Dose-related psychotic symptoms in chronic methamphetamine users: evidence from a prospective longitudinal study. JAMA Psychiatry. 2013;70(3):319–24. This longitudinal study demonstrates a strong dose-dependent increase in the occurrence of psychotic symptoms during periods of methamphetamine use among individuals who use the drug regularly.
15. Srisurapanont M et al. Psychotic symptoms in methamphetamine psychotic in-patients. Int J Neuropsychopharmacol. 2003;6(4):347–52.
16. Zorick T et al. Withdrawal symptoms in abstinent methamphetamine-dependent subjects. Addiction. 2010;105(10):1809–18.
17. Fasihpour B, Molavi S, Shariat SV. Clinical features of inpatients with methamphetamine-induced psychosis. J Ment Health. 2013;22(4):341–9.
18. Chen CK et al. Pre-morbid characteristics and co-morbidity of methamphetamine users with and without psychosis. Psychol Med. 2003;33(8):1407–14.
19. Kittirattanapaiboon P et al. Long-term outcomes in methamphetamine psychosis patients after first hospitalisation. Drug Alcohol Rev. 2010;29(4):456–61.
20. Hides L et al. Primary and substance-induced psychotic disorders in methamphetamine users. Psychiatry Res. 2015;226(1):91–6.
21. Lichlyter B, Purdon S, Tibbo P. Predictors of psychosis severity in individuals with primary stimulant addictions. Addict Behav. 2011;36(1–2):137–9.
22. Lecomte T et al. Predictors of persistent psychotic symptoms in persons with methamphetamine abuse receiving psychiatric treatment. J Nerv Ment Dis. 2013;201(12):1085–9.
23. Smith MJ et al. Prevalence of psychotic symptoms in substance users: a comparison across substances. Compr Psychiatry. 2009;50(3):245–50.
24. Rognli EB et al. Does the pattern of amphetamine use prior to incarceration predict later psychosis?—a longitudinal study of amphetamine users in the Swedish criminal justice system. Drug Alcohol Depend. 2014;143:219–24.
25. Salo R et al. Findings of preserved implicit attention in methamphetamine dependent subjects. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(1):217–23.
26. Batki SL, Harris DS. Quantitative drug levels in stimulant psychosis: relationship to symptom severity, catecholamines and hyperkinesia. Am J Addict. 2004;13(5):461–70.
27. Medhus S et al. A comparison of symptoms and drug use between patients with methamphetamine associated psychoses and patients diagnosed with schizophrenia in two acute psychiatric wards. Psychiatry Res. 2013;206(1):17–21. This study found no difference in positive symptoms when comparing patients with acute psychosis with and without positive testing for methamphetamine. The implication is that in the acute phase, schizophrenia and methamphetamine-associated psychosis is very difficult to tell apart. This study also speaks against a dose–response relationship between amount of methamphetamine used and the occurrence of psychotic symptoms.
28. Sato M et al. Acute exacerbation of paranoid psychotic state after long-term abstinence in patients with previous methamphetamine psychosis. Biol Psychiatry. 1983;18(4):429–40.
29. Sato M, Numachi Y, Hamamura T. Relapse of paranoid psychotic state in methamphetamine model of schizophrenia. Schizophr Bull. 1992;18(1):115–22.
30. Iwanami A et al. Patients with methamphetamine psychosis admitted to a psychiatric hospital in Japan. A preliminary report. Acta Psychiatr Scand. 1994;89(6):428–32.
31. Konuma K. Use and abuse of amphetamines in Japan. In: Cho AK, Segal DS, editors. Amphetamine and its analogs—psychopharmacology, toxicology and abuse. San Diego: Academic; 1994.
32. Akiyama K. Longitudinal clinical course following pharmacological treatment of methamphetamine psychosis which persists after long-term abstinence. Ann N Y Acad Sci. 2006;1074:125–34.
33. Ujike H, Sato M. Clinical features of sensitization to methamphetamine observed in patients with methamphetamine dependence and psychosis. Ann N Y Acad Sci. 2004;1025:279–87.
34. Gururajan A et al. Drugs of abuse and increased risk of psychosis development. Aust N Z J Psychiatry. 2012;46(12):1120–35.
35. Callaghan RC et al. Methamphetamine use and schizophrenia: a population-based cohort study in California. Am J Psychiatry. 2012;169(4):389–96. This is a large, register based, longitudinal study that compares 42.412 individuals who have been hospitalized for a methamphetamine-related condition to a proxy of the normal population. The methamphetamine cohort had more than 9 times increased risk of developing schizophrenia, and this study thus demonstrates methamphetamine use as a risk factor for schizophrenia.
36. Niemi-Pynttari JA et al. Substance-induced psychoses converting into schizophrenia: a register-based study of 18,478 Finnish inpatient cases. J Clin Psychiatry. 2013;74(1):e94–9. This study is the largest longitudinal study to investigate the transition from amphetamine-induced psychosis to primary psychosis. The eight-year cumulative risk to receive a schizophrenia-spectrum diagnosis was 30 %. This study thus demonstrates amphetamine-induced psychosis as a relatively strong risk factor for schizophrenia.
37. Mathias S, Lubman DI, Hides L. Substance-induced psychosis: a diagnostic conundrum. J Clin Psychiatry. 2008;69(3):358–67.
38. Ding Y et al. Adverse childhood experiences and interaction with methamphetamine use frequency in the risk of methamphetamine-associated psychosis. Drug Alcohol Depend. 2014;142:295–300.
39. Regier DA et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA. 1990;264(19):2511–8.
40. Jablensky A et al. Psychotic disorders in urban areas: an overview of the study on low prevalence disorders. Aust N Z J Psychiatry. 2000;34(2):221–36.
41. Brady KT, Sinha R. Co-occurring mental and substance use disorders: the neurobiological effects of chronic stress. Am J Psychiatry. 2005;162(8):1483–93.
42. Chambers RA, Krystal JH, Self DW. A neurobiological basis for substance abuse comorbidity in schizophrenia. Biol Psychiatry. 2001;50(2):71–83.
43. Khantzian EJ. The self-medication hypothesis of substance use disorders: a reconsideration and recent applications. Harv Rev Psychiatry. 1997;4(5):231–44.
44. Wobrock T et al. Comorbid substance abuse in first-episode schizophrenia: effects on cognition and psychopathology in the EUFEST study. Schizophr Res. 2013;147(1):132–9.
45. Mauri MC et al. Substance abuse in first-episode schizophrenic patients: a retrospective study. Clin Pract Epidemiol Ment Health. 2006;2:4.
46. Green AI et al. Detection and management of comorbidity in patients with schizophrenia. Psychiatr Clin North Am. 2003;26(1):115–39.
47. Loberg EM et al. The cannabis pathway to non-affective psychosis may reflect less neurobiological vulnerability. Front Psychiatry. 2014;5:159.
48. DeQuardo JR, Carpenter CF, Tandon R. Patterns of substance abuse in schizophrenia: nature and significance. J Psychiatr Res. 1994;28(3):267–75.
49. Helseth V et al. Substance use disorders among psychotic patients admitted to inpatient psychiatric care. Nord J Psychiatry. 2009;63(1):72–7.
50. Barnett JH et al. Substance use in a population-based clinic sample of people with first-episode psychosis. Br J Psychiatry. 2007;190:515–20.
51. Sara GE et al. Stimulant use disorders in people with psychosis: a meta-analysis of rate and factors affecting variation. Aust N Z J Psychiatry. 2015;49(2):106–17. This meta-analysis found that among individuals with psychosis, cannabis use disorders were the strongest correlate of the prevalence of stimulant use disorders. This points to a possibility that amphetamine and cannabis together may affect and interact with psychosis.
52. Salo R et al. Attentional control and brain metabolite levels in methamphetamine abusers. Biol Psychiatry. 2007;61(11):1272–80.
53. Chen CK et al. Morbid risk for psychiatric disorder among the relatives of methamphetamine users with and without psychosis. Am J Med Genet B Neuropsychiatr Genet. 2005;136(1):87–91.
54. Sulaiman AH et al. The risk and associated factors of methamphetamine psychosis in methamphetamine-dependent patients in Malaysia. Compr Psychiatry. 2014;55 Suppl 1:S89–94.
55. Petrovsky N et al. Sleep deprivation disrupts prepulse inhibition and induces psychosis-like symptoms in healthy humans. J Neurosci. 2014;34(27):9134–40.
56. Bell DS. Comparison of amphetamine psychosis and schizophrenia. Br J Psychiatry. 1965;111:701–7.
57. Ellinwood E. Amphetamine psychosis: I. description of individuals and process. J Nerv Ment Dis. 1967;144:273–83.
58. Bousman CA et al. Methamphetamine-associated psychosis: a model for biomarker discovery in schizophrenia in handbook of schizophrenia spectrum disorders, M.S. Ritsner, Editor. 2011, Springer: Amsterdam.
59. Curran C, Byrappa N, McBride A. Stimulant psychosis: systematic review. Br J Psychiatry. 2004;185:196–204.
60. Caton C et al. Differences between early-phase primary psychotic disorder with concurrent substance use and substance-induced psychosis. Arch Gen Psychiatry. 2005;62:137–45.
61. American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorder, Fourth edition, Text Revision (DSM-IV-TR). 2000, Arlington: American Psychiatric Association.
62. Akiyama K, Saito A, Shimoda K. Chronic methamphetamine psychosis after long-term abstinence in Japanese incarcerated patients. Am J Addict. 2011;20(3):240–9.
63. Hasin D et al. Diagnosis of comorbid psychiatric disorders in substance users assessed with the psychiatric research interview for substance and mental disorders for DSM-IV. Am J Psychiatry. 2006;163(4):689–96.
64. Caton CL et al. Stability of early-phase primary psychotic disorders with concurrent substance use and substance-induced psychosis. Br J Psychiatry. 2007;190:105–11.
65. Bramness JG et al. Amphetamine-induced psychosis—a separate diagnostic entity or primary psychosis triggered in the vulnerable? BMC Psychiatry. 2012;12:221. This article questions the validity of amphetamine-induced psychosis as a separate diagnostic entity, and suggests that the relationship between amphetamine use and psychosis is best understood within a stress-vulnerability model.
66. Sato M. A lasting vulnerability to psychosis in patients with previous methamphetamine psychosis. Ann N Y Acad Sci. 1992;654:160–70.
67. Verdoux H, van Os J. Psychotic symptoms in non-clinical populations and the continuum of psychosis. Schizophr Res. 2002;54(1–2):59–65.
68. van Os J et al. A systematic review and meta-analysis of the psychosis continuum: evidence for a psychosis proneness-persistence-impairment model of psychotic disorder. Psychol Med. 2009;39(2):179–95.
69. Ericsson E, Bradvik L, Hakansson A. Mortality, causes of death and risk factors for death among primary amphetamine users in the Swedish criminal justice system. Subst Use Misuse. 2014;49(3):262–9.
70. Kuo CJ et al. Causes of death of patients with methamphetamine dependence: a record-linkage study. Drug Alcohol Rev. 2011;30(6):621–8.
71. Kaye S et al. Methamphetamine-related fatalities in Australia: demographics, circumstances, toxicology and major organ pathology. Addiction. 2008;103(8):1353–60.
72. Henry BL, Minassian A, Perry W. Effect of methamphetamine dependence on heart rate variability. Addict Biol. 2012;17(3):648–58.
73. Haning W, Goebert D. Electrocardiographic abnormalities in methamphetamine abusers. Addiction. 2007;102 Suppl 1:70–5.
74. Parks J et al. Morbidity and mortality in people with serious mental illness. 2006: National Association of State Mental Health Program Directors (NASMHPD) Medical Directors Council Alexandria, VA.
75. Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry. 2007;64(10):1123–31.
76. Hennekens CH et al. Schizophrenia and increased risks of cardiovascular disease. Am Heart J. 2005;150(6):1115–21.
77. Medhus S et al. Amphetamine-induced psychosis: transition to schizophrenia and mortality in a small clinical sample. Am J Addict, 2015. in press. This article demonstrates similar transition rates from amphetamine-induced psychosis to schizophrenia as that found in other studies, and also finds a disturbingly high death rate.
78. Richards JR et al. Treatment of toxicity from amphetamines, related derivatives, and analogues: a systematic clinical review. Drug Alcohol Depend. 2015;150:1–13.
79. McIver C et al. Guidelines for the medical management of patients with methamphetamine-induced psychosis. Australia: G.o.S; 2006.
80. NICE, Psychosis with coexisting substance misuse. Clinical guideline 120, N.c.c.f.m. health, Editor. 2011: London.
81. NICE, Schizophrenia: core interventions in the treatment of and management of schizophrenia in primary and secondary care, N.c.c.f.m. health, Editor. 2009: London.
82. Shoptaw SJ, Kao U, Ling W. Treatment for amphetamine psychosis. Cochrane Database Syst Rev. 2009;1, CD003026.
83. Glasner-Edwards S, Mooney LJ. Methamphetamine psychosis: epidemiology and management. CNS Drugs. 2014;28(12):1115–26.
84. Mueser TM et al. Integrated treatment for dual disorder. A guide to effective practice. New York: The Guilford Press; 2003.
85. Lambert M et al. The impact of substance use disorders on clinical outcome in 643 patients with first-episode psychosis. Acta Psychiatr Scand. 2005;112(2):141–8.
86. Whitty P et al. Diagnostic stability four years after a first episode of psychosis. Psychiatr Serv. 2005;56(9):1084–8.
87. Crebbin K et al. First-episode drug-induced psychosis: a medium term follow up study reveals a high-risk group. Soc Psychiatry Psychiatr Epidemiol. 2009;44(9):710–5.
88. Pedros A et al. Two-year diagnostic stability and prognosis in acute psychotic episodes. Actas Esp Psiquiatr. 2009;37(5):245–51.